

Nuclear Medicine Global Market Outlook - Trends, Forecast, and Opportunity Assessment (2014-2022)

<https://marketpublishers.com/r/N00B7F296BBEN.html>

Date: September 2015

Pages: 175

Price: US\$ 4,150.00 (Single User License)

ID: N00B7F296BBEN

Abstracts

The Global Nuclear Medicine Market accounted for \$8.8 billion in 2014 and is expected to grow at a CAGR of 9.6% to reach \$20.4 billion by 2022. Nuclear medicine uses radiation to provide diagnostic information about the functioning of a person's specific organs, or to treat them. According to World nuclear association, Over 10,000 hospitals across the world use radioisotopes in medicine, and about 90% of the procedures are for diagnosis. The most commonly used radioisotope in diagnosis is technetium-99, accounting for more than 80% of all nuclear medicine procedures worldwide. Computed X-ray tomography (CT) scans and nuclear medicine contribute 36% of the total radiation exposure and 75% of the medical exposure to the U.S. population, according to a US National Council on Radiation Protection & Measurements report.

Factors driving the nuclear medicine market include advancements in radiotracers, increasing number of patients with cancer and cardiovascular ailment, increasing use of SPECT and PET scan results and alpha radio immunotherapy-based targeted cancer treatment. However, factors such as stringent regulatory guidelines, high capital investment, shorter half-life of radiopharmaceuticals and competition from conventional diagnostic procedures are inhibiting the growth of nuclear medicine market. Technological advancements in neurological applications and increasing demand from emerging countries are likely to create huge opportunities for the market growth.

The Global nuclear medicine market is segmented on the basis of type, application and geography. By type, the market is classified into nuclear medicine diagnostic market and nuclear medicine therapeutic isotopes market. Based on the application, the nuclear medicine market is categorized into diagnostics and therapeutics applications. The diagnostic application is further segmented into SPECT and PET market, where SPECT market comprises cardiology, neurology, thyroid and other diagnostic

applications. The PET market comprises oncology and other PET applications. The therapeutics application is further segmented into thyroid, bone metastasis, endocrine tumors and other therapeutic applications. By geography, it is segmented into North America, Europe, Asia Pacific and Rest of the World. North America followed by the Europe dominates the global nuclear medicine market.

Some of the key players in nuclear medicine market include GE Healthcare (U.K.), Nordion, Inc. (Canada), Bayer Healthcare (Germany), Cardinal Health, Inc. (U.S.), Siemens Healthcare (PETNET) (Germany), IBA Group (Belgium), Lantheus Medical Imaging, Inc. (U.S.), Eczacibasi-Monrol Nuclear Products (Turkey), Ashby Gorman Baker Ltd, and Mediso Ltd.

WHAT OUR REPORT OFFERS:

Market share assessments for the regional and country level segments

Market share analysis of the top industry players

Strategic recommendations for the new entrants

Market forecasts for a minimum of 8 years of all the mentioned segments, sub segments and the regional markets

Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

Strategic recommendations in key business segments based on the market estimations

Competitive landscaping mapping the key common trends

Company profiling with detailed strategies, financials, and recent developments

Supply chain trends mapping the latest technological advancements

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

- 2.1 Abstract
- 2.2 Research Scope
- 2.3 Research Methodology
- 2.4 Research Sources

3 MARKET TREND ANALYSIS

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats

4 PORTERS FIVE FORCE ANALYSIS

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 GLOBAL NUCLEAR MEDICINE MARKET, BY TYPE

- 5.1 Introduction
- 5.2 Nuclear Medicine Diagnostic Market
 - 5.2.1 SPECT
 - 5.2.1.1 Introduction
 - 5.2.1.2 Gallium-67 (GA-67)
 - 5.2.1.3 Technetium-99m (TC-99m)
 - 5.2.1.4 Others
 - 5.2.2 PET
 - 5.2.2.1 Introduction
 - 5.2.2.2 Fluorine-18 (F-18)

5.2.2.3 Rubidium-82 (RB-82)

5.2.2.4 Others

5.3 Nuclear Medicine Therapeutic Isotopes Market

5.3.1 Alpha Emitters

5.3.1.1 Introduction

5.3.1.2 Radium-223 (RA-223)

5.3.2 Beta Emitters

5.3.2.1 Introduction

5.3.2.2 Yttrium-90 (Y-90)

5.3.2.3 Samarium-153 (SM-153)

5.3.2.4 Lutetium-177 (Lu-177)

5.3.3 Brachytherapy

5.3.3.1 Iodine-125

5.3.3.2 Palladium-103

5.3.3.3 Cesium-131

5.3.3.4 Others

6 GLOBAL NUCLEAR MEDICINE MARKET, BY APPLICATIONS

6.1 Introduction

6.2 Diagnostics

6.2.1 Single proton emission tomography (SPECT)

6.2.1.1 Cardiology

6.2.1.2 Neurology

6.2.1.3 Thyroid

6.2.1.4 Other SPECT applications

6.2.2 Positron emission tomography (PET)

6.2.2.1 Oncology

6.2.2.2 Other PET applications

6.3 Therapeutics

6.3.1 Thyroid

6.3.2 Bone metastasis

6.3.3 Endocrine tumors

6.3.4 Other therapeutic applications

7 GLOBAL NUCLEAR MEDICINE MARKET, BY GEOGRAPHY

7.1 North America

7.1.1 US

- 7.1.2 Canada
- 7.2 Europe
 - 7.2.1 Germany
 - 7.2.2 France
 - 7.2.3 Italy
 - 7.2.4 UK
 - 7.2.5 Spain
- 7.3 Asia Pacific
 - 7.3.1 Japan
 - 7.3.2 China
 - 7.3.3 India
 - 7.3.4 Australia
 - 7.3.5 New Zealand
 - 7.3.7 Rest of Asia
- 7.4 Rest of the World
 - 7.4.1 Latin America
 - 7.4.2 Middle East
 - 7.4.3 Africa
 - 7.4.4 Others

8 KEY DEVELOPMENTS

- 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 8.2 Acquisitions & Mergers
- 8.3 New Product Launch
- 8.4 Expansions
- 8.5 Other Key Strategies

9 COMPANY PROFILING

- 9.1 GE Healthcare (U.K.)
- 9.2 Nordion, Inc. (Canada)
- 9.3 Bayer Healthcare (Germany)
- 9.4 Cardinal Health, Inc. (U.S.)
- 9.5 Siemens Healthcare (PETNET) (Germany)
- 9.6 IBA Group (Belgium)
- 9.7 Lantheus Medical Imaging, Inc. (U.S.)
- 9.8 Eczacibasi-Monrol Nuclear Products (Turkey)
- 9.9 Ashby Gorman Baker Ltd

9.10 Mediso Ltd.

List Of Tables

LIST OF TABLES

- 1 Global Nuclear Medicine Market Outlook, By Type (2012-2022) (\$MN)
- 2 Global Nuclear Medicine Market Outlook, By Nuclear Medicine Diagnostic Market (2012-2022) (\$MN)
- 3 Global Nuclear Medicine Market Outlook, By SPECT (2012-2022) (\$MN)
- 4 Global Nuclear Medicine Market Outlook, By Gallium-67 (GA-67) (2012-2022) (\$MN)
- 5 Global Nuclear Medicine Market Outlook, By Technetium-99m (TC-99m) (2012-2022) (\$MN)
- 6 Global Nuclear Medicine Market Outlook, By Others (2012-2022) (\$MN)
- 7 Global Nuclear Medicine Market Outlook, By PET (2012-2022) (\$MN)
- 8 Global Nuclear Medicine Market Outlook, By Fluorine-18 (F-18) (2012-2022) (\$MN)
- 9 Global Nuclear Medicine Market Outlook, By Rubidium-82 (RB-82) (2012-2022) (\$MN)
- 10 Global Nuclear Medicine Market Outlook, By Others (2012-2022) (\$MN)
- 11 Global Nuclear Medicine Market Outlook, By Nuclear Medicine Therapeutic Isotopes Market (2012-2022) (\$MN)
- 12 Global Nuclear Medicine Market Outlook, By Alpha Emitters (2012-2022) (\$MN)
- 13 Global Nuclear Medicine Market Outlook, By Radium-223 (RA-223) (2012-2022) (\$MN)
- 14 Global Nuclear Medicine Market Outlook, By Beta Emitters (2012-2022) (\$MN)
- 15 Global Nuclear Medicine Market Outlook, By Yttrium-90 (Y-90) (2012-2022) (\$MN)
- 16 Global Nuclear Medicine Market Outlook, By Samarium-153 (SM-153) (2012-2022) (\$MN)
- 17 Global Nuclear Medicine Market Outlook, By Lutetium-177 (Lu-177) (2012-2022) (\$MN)
- 18 Global Nuclear Medicine Market Outlook, By Brachytherapy (2012-2022) (\$MN)
- 19 Global Nuclear Medicine Market Outlook, By Iodine-125 (2012-2022) (\$MN)
- 20 Global Nuclear Medicine Market Outlook, By Palladium-103 (2012-2022) (\$MN)
- 21 Global Nuclear Medicine Market Outlook, By Cesium-131 (2012-2022) (\$MN)
- 22 Global Nuclear Medicine Market Outlook, By Others (2012-2022) (\$MN)
- 23 Global Nuclear Medicine Market Outlook, By Applications (2012-2022) (\$MN)
- 24 Global Nuclear Medicine Market Outlook, By Diagnostics (2012-2022) (\$MN)
- 25 Global Nuclear Medicine Market Outlook, By Single proton emission tomography (SPECT) (2012-2022) (\$MN)
- 26 Global Nuclear Medicine Market Outlook, By Cardiology (2012-2022) (\$MN)
- 27 Global Nuclear Medicine Market Outlook, By Neurology (2012-2022) (\$MN)

- 28 Global Nuclear Medicine Market Outlook, By Thyroid (2012-2022) (\$MN)
- 29 Global Nuclear Medicine Market Outlook, By Other SPECT applications (2012-2022) (\$MN)
- 30 Global Nuclear Medicine Market Outlook, By Positron emission tomography (PET) (2012-2022) (\$MN)
- 31 Global Nuclear Medicine Market Outlook, By Oncology (2012-2022) (\$MN)
- 32 Global Nuclear Medicine Market Outlook, By Other PET applications (2012-2022) (\$MN)
- 33 Global Nuclear Medicine Market Outlook, By Therapeutics (2012-2022) (\$MN)
- 34 Global Nuclear Medicine Market Outlook, By Thyroid (2012-2022) (\$MN)
- 35 Global Nuclear Medicine Market Outlook, By Bone metastasis (2012-2022) (\$MN)
- 36 Global Nuclear Medicine Market Outlook, By Endocrine tumors (2012-2022) (\$MN)
- 37 Global Nuclear Medicine Market Outlook, By Other therapeutic applications (2012-2022) (\$MN)
- 38 North America Nuclear Medicine Market Outlook, By Type (2012-2022) (\$MN)
- 39 North America Nuclear Medicine Market Outlook, By Nuclear Medicine Diagnostic Market (2012-2022) (\$MN)
- 40 North America Nuclear Medicine Market Outlook, By SPECT (2012-2022) (\$MN)
- 41 North America Nuclear Medicine Market Outlook, By Gallium-67 (GA-67) (2012-2022) (\$MN)
- 42 North America Nuclear Medicine Market Outlook, By Technetium-99m (TC-99m) (2012-2022) (\$MN)
- 43 North America Nuclear Medicine Market Outlook, By Others (2012-2022) (\$MN)
- 44 North America Nuclear Medicine Market Outlook, By PET (2012-2022) (\$MN)
- 45 North America Nuclear Medicine Market Outlook, By Fluorine-18 (F-18) (2012-2022) (\$MN)
- 46 North America Nuclear Medicine Market Outlook, By Rubidium-82 (RB-82) (2012-2022) (\$MN)
- 47 North America Nuclear Medicine Market Outlook, By Others (2012-2022) (\$MN)
- 48 North America Nuclear Medicine Market Outlook, By Nuclear Medicine Therapeutic Isotopes Market (2012-2022) (\$MN)
- 49 North America Nuclear Medicine Market Outlook, By Alpha Emitters (2012-2022) (\$MN)
- 50 North America Nuclear Medicine Market Outlook, By Radium-223 (RA-223) (2012-2022) (\$MN)
- 51 North America Nuclear Medicine Market Outlook, By Beta Emitters (2012-2022) (\$MN)
- 52 North America Nuclear Medicine Market Outlook, By Yttrium-90 (Y-90) (2012-2022) (\$MN)

- 53 North America Nuclear Medicine Market Outlook, By Samarium-153 (SM-153) (2012-2022) (\$MN)
- 54 North America Nuclear Medicine Market Outlook, By Lutetium-177 (Lu-177) (2012-2022) (\$MN)
- 55 North America Nuclear Medicine Market Outlook, By Brachytherapy (2012-2022) (\$MN)
- 56 North America Nuclear Medicine Market Outlook, By Iodine-125 (2012-2022) (\$MN)
- 57 North America Nuclear Medicine Market Outlook, By Palladium-103 (2012-2022) (\$MN)
- 58 North America Nuclear Medicine Market Outlook, By Cesium-131 (2012-2022) (\$MN)
- 59 North America Nuclear Medicine Market Outlook, By Others (2012-2022) (\$MN)
- 60 North America Nuclear Medicine Market Outlook, By Applications (2012-2022) (\$MN)
- 61 North America Nuclear Medicine Market Outlook, By Diagnostics (2012-2022) (\$MN)
- 62 North America Nuclear Medicine Market Outlook, By Single proton emission tomography (SPECT) (2012-2022) (\$MN)
- 63 North America Nuclear Medicine Market Outlook, By Cardiology (2012-2022) (\$MN)
- 64 North America Nuclear Medicine Market Outlook, By Neurology (2012-2022) (\$MN)
- 65 North America Nuclear Medicine Market Outlook, By Thyroid (2012-2022) (\$MN)
- 66 North America Nuclear Medicine Market Outlook, By Other SPECT applications (2012-2022) (\$MN)
- 67 North America Nuclear Medicine Market Outlook, By Positron emission tomography (PET) (2012-2022) (\$MN)
- 68 North America Nuclear Medicine Market Outlook, By Oncology (2012-2022) (\$MN)
- 69 North America Nuclear Medicine Market Outlook, By Other PET applications (2012-2022) (\$MN)
- 70 North America Nuclear Medicine Market Outlook, By Therapeutics (2012-2022) (\$MN)
- 71 North America Nuclear Medicine Market Outlook, By Thyroid (2012-2022) (\$MN)
- 72 North America Nuclear Medicine Market Outlook, By Bone metastasis (2012-2022) (\$MN)
- 73 North America Nuclear Medicine Market Outlook, By Endocrine tumors (2012-2022) (\$MN)
- 74 North America Nuclear Medicine Market Outlook, By Other therapeutic applications (2012-2022) (\$MN)
- 75 Europe Nuclear Medicine Market Outlook, By Type (2012-2022) (\$MN)
- 76 Europe Nuclear Medicine Market Outlook, By Nuclear Medicine Diagnostic Market (2012-2022) (\$MN)

- 77 Europe Nuclear Medicine Market Outlook, By SPECT (2012-2022) (\$MN)
- 78 Europe Nuclear Medicine Market Outlook, By Gallium-67 (GA-67) (2012-2022) (\$MN)
- 79 Europe Nuclear Medicine Market Outlook, By Technetium-99m (TC-99m) (2012-2022) (\$MN)
- 80 Europe Nuclear Medicine Market Outlook, By Others (2012-2022) (\$MN)
- 81 Europe Nuclear Medicine Market Outlook, By PET (2012-2022) (\$MN)
- 82 Europe Nuclear Medicine Market Outlook, By Fluorine-18 (F-18) (2012-2022) (\$MN)
- 83 Europe Nuclear Medicine Market Outlook, By Rubidium-82 (RB-82) (2012-2022) (\$MN)
- 84 Europe Nuclear Medicine Market Outlook, By Others (2012-2022) (\$MN)
- 85 Europe Nuclear Medicine Market Outlook, By Nuclear Medicine Therapeutic Isotopes Market (2012-2022) (\$MN)
- 86 Europe Nuclear Medicine Market Outlook, By Alpha Emitters (2012-2022) (\$MN)
- 87 Europe Nuclear Medicine Market Outlook, By Radium-223 (RA-223) (2012-2022) (\$MN)
- 88 Europe Nuclear Medicine Market Outlook, By Beta Emitters (2012-2022) (\$MN)
- 89 Europe Nuclear Medicine Market Outlook, By Yttrium-90 (Y-90) (2012-2022) (\$MN)
- 90 Europe Nuclear Medicine Market Outlook, By Samarium-153 (SM-153) (2012-2022) (\$MN)
- 91 Europe Nuclear Medicine Market Outlook, By Lutetium-177 (Lu-177) (2012-2022) (\$MN)
- 92 Europe Nuclear Medicine Market Outlook, By Brachytherapy (2012-2022) (\$MN)
- 93 Europe Nuclear Medicine Market Outlook, By Iodine-125 (2012-2022) (\$MN)
- 94 Europe Nuclear Medicine Market Outlook, By Palladium-103 (2012-2022) (\$MN)
- 95 Europe Nuclear Medicine Market Outlook, By Cesium-131 (2012-2022) (\$MN)
- 96 Europe Nuclear Medicine Market Outlook, By Others (2012-2022) (\$MN)
- 97 Europe Nuclear Medicine Market Outlook, By Applications (2012-2022) (\$MN)
- 98 Europe Nuclear Medicine Market Outlook, By Diagnostics (2012-2022) (\$MN)
- 99 Europe Nuclear Medicine Market Outlook, By Single proton emission tomography (SPECT) (2012-2022) (\$MN)
- 100 Europe Nuclear Medicine Market Outlook, By Cardiology (2012-2022) (\$MN)
- 101 Europe Nuclear Medicine Market Outlook, By Neurology (2012-2022) (\$MN)
- 102 Europe Nuclear Medicine Market Outlook, By Thyroid (2012-2022) (\$MN)
- 103 Europe Nuclear Medicine Market Outlook, By Other SPECT applications (2012-2022) (\$MN)
- 104 Europe Nuclear Medicine Market Outlook, By Positron emission tomography (PET) (2012-2022) (\$MN)
- 105 Europe Nuclear Medicine Market Outlook, By Oncology (2012-2022) (\$MN)

- 106 Europe Nuclear Medicine Market Outlook, By Other PET applications (2012-2022) (\$MN)
- 107 Europe Nuclear Medicine Market Outlook, By Therapeutics (2012-2022) (\$MN)
- 108 Europe Nuclear Medicine Market Outlook, By Thyroid (2012-2022) (\$MN)
- 109 Europe Nuclear Medicine Market Outlook, By Bone metastasis (2012-2022) (\$MN)
- 110 Europe Nuclear Medicine Market Outlook, By Endocrine tumors (2012-2022) (\$MN)
- 111 Europe Nuclear Medicine Market Outlook, By Other therapeutic applications (2012-2022) (\$MN)
- 112 Asia Pacific Nuclear Medicine Market Outlook, By Type (2012-2022) (\$MN)
- 113 Asia Pacific Nuclear Medicine Market Outlook, By Nuclear Medicine Diagnostic Market (2012-2022) (\$MN)
- 114 Asia Pacific Nuclear Medicine Market Outlook, By SPECT (2012-2022) (\$MN)
- 115 Asia Pacific Nuclear Medicine Market Outlook, By Gallium-67 (GA-67) (2012-2022) (\$MN)
- 116 Asia Pacific Nuclear Medicine Market Outlook, By Technetium-99m (TC-99m) (2012-2022) (\$MN)
- 117 Asia Pacific Nuclear Medicine Market Outlook, By Others (2012-2022) (\$MN)
- 118 Asia Pacific Nuclear Medicine Market Outlook, By PET (2012-2022) (\$MN)
- 119 Asia Pacific Nuclear Medicine Market Outlook, By Fluorine-18 (F-18) (2012-2022) (\$MN)
- 120 Asia Pacific Nuclear Medicine Market Outlook, By Rubidium-82 (RB-82) (2012-2022) (\$MN)
- 121 Asia Pacific Nuclear Medicine Market Outlook, By Others (2012-2022) (\$MN)
- 122 Asia Pacific Nuclear Medicine Market Outlook, By Nuclear Medicine Therapeutic Isotopes Market (2012-2022) (\$MN)
- 123 Asia Pacific Nuclear Medicine Market Outlook, By Alpha Emitters (2012-2022) (\$MN)
- 124 Asia Pacific Nuclear Medicine Market Outlook, By Radium-223 (RA-223) (2012-2022) (\$MN)
- 125 Asia Pacific Nuclear Medicine Market Outlook, By Beta Emitters (2012-2022) (\$MN)
- 126 Asia Pacific Nuclear Medicine Market Outlook, By Yttrium-90 (Y-90) (2012-2022) (\$MN)
- 127 Asia Pacific Nuclear Medicine Market Outlook, By Samarium-153 (SM-153) (2012-2022) (\$MN)
- 128 Asia Pacific Nuclear Medicine Market Outlook, By Lutetium-177 (Lu-177) (2012-2022) (\$MN)
- 129 Asia Pacific Nuclear Medicine Market Outlook, By Brachytherapy (2012-2022) (\$MN)
- 130 Asia Pacific Nuclear Medicine Market Outlook, By Iodine-125 (2012-2022) (\$MN)

- 131 Asia Pacific Nuclear Medicine Market Outlook, By Palladium-103 (2012-2022) (\$MN)
- 132 Asia Pacific Nuclear Medicine Market Outlook, By Cesium-131 (2012-2022) (\$MN)
- 133 Asia Pacific Nuclear Medicine Market Outlook, By Others (2012-2022) (\$MN)
- 134 Asia Pacific Nuclear Medicine Market Outlook, By Applications (2012-2022) (\$MN)
- 135 Asia Pacific Nuclear Medicine Market Outlook, By Diagnostics (2012-2022) (\$MN)
- 136 Asia Pacific Nuclear Medicine Market Outlook, By Single proton emission tomography (SPECT) (2012-2022) (\$MN)
- 137 Asia Pacific Nuclear Medicine Market Outlook, By Cardiology (2012-2022) (\$MN)
- 138 Asia Pacific Nuclear Medicine Market Outlook, By Neurology (2012-2022) (\$MN)
- 139 Asia Pacific Nuclear Medicine Market Outlook, By Thyroid (2012-2022) (\$MN)
- 140 Asia Pacific Nuclear Medicine Market Outlook, By Other SPECT applications (2012-2022) (\$MN)
- 141 Asia Pacific Nuclear Medicine Market Outlook, By Positron emission tomography (PET) (2012-2022) (\$MN)
- 142 Asia Pacific Nuclear Medicine Market Outlook, By Oncology (2012-2022) (\$MN)
- 143 Asia Pacific Nuclear Medicine Market Outlook, By Other PET applications (2012-2022) (\$MN)
- 144 Asia Pacific Nuclear Medicine Market Outlook, By Therapeutics (2012-2022) (\$MN)
- 145 Asia Pacific Nuclear Medicine Market Outlook, By Thyroid (2012-2022) (\$MN)
- 146 Asia Pacific Nuclear Medicine Market Outlook, By Bone metastasis (2012-2022) (\$MN)
- 147 Asia Pacific Nuclear Medicine Market Outlook, By Endocrine tumors (2012-2022) (\$MN)
- 148 Asia Pacific Nuclear Medicine Market Outlook, By Other therapeutic applications (2012-2022) (\$MN)
- 149 Rest Of The World Nuclear Medicine Market Outlook, By Type (2012-2022) (\$MN)
- 150 Rest Of The World Nuclear Medicine Market Outlook, By Nuclear Medicine Diagnostic Market (2012-2022) (\$MN)
- 151 Rest Of The World Nuclear Medicine Market Outlook, By SPECT (2012-2022) (\$MN)
- 152 Rest Of The World Nuclear Medicine Market Outlook, By Gallium-67 (GA-67) (2012-2022) (\$MN)
- 153 Rest Of The World Nuclear Medicine Market Outlook, By Technetium-99m (TC-99m) (2012-2022) (\$MN)
- 154 Rest Of The World Nuclear Medicine Market Outlook, By Others (2012-2022) (\$MN)
- 155 Rest Of The World Nuclear Medicine Market Outlook, By PET (2012-2022) (\$MN)
- 156 Rest Of The World Nuclear Medicine Market Outlook, By Fluorine-18 (F-18)

(2012-2022) (\$MN)

157 Rest Of The World Nuclear Medicine Market Outlook, By Rubidium-82 (RB-82)

(2012-2022) (\$MN)

158 Rest Of The World Nuclear Medicine Market Outlook, By Others (2012-2022)

(\$MN)

159 Rest Of The World Nuclear Medicine Market Outlook, By Nuclear Medicine
Therapeutic Isotopes Market (2012-2022) (\$MN)

160 Rest Of The World Nuclear Medicine Market Outlook, By Alpha Emitters

(2012-2022) (\$MN)

161 Rest Of The World Nuclear Medicine Market Outlook, By Radium-223 (RA-223)

(2012-2022) (\$MN)

162 Rest Of The World Nuclear Medicine Market Outlook, By Beta Emitters

(2012-2022) (\$MN)

163 Rest Of The World Nuclear Medicine Market Outlook, By Yttrium-90 (Y-90)

(2012-2022) (\$MN)

164 Rest Of The World Nuclear Medicine Market Outlook, By Samarium-153 (SM-153)

(2012-2022) (\$MN)

165 Rest Of The World Nuclear Medicine Market Outlook, By Lutetium-177 (Lu-177)

(2012-2022) (\$MN)

166 Rest Of The World Nuclear Medicine Market Outlook, By Brachytherapy

(2012-2022) (\$MN)

167 Rest Of The World Nuclear Medicine Market Outlook, By Iodine-125 (2012-2022)

(\$MN)

168 Rest Of The World Nuclear Medicine Market Outlook, By Palladium-103

(2012-2022) (\$MN)

169 Rest Of The World Nuclear Medicine Market Outlook, By Cesium-131 (2012-2022)

(\$MN)

170 Rest Of The World Nuclear Medicine Market Outlook, By Others (2012-2022)

(\$MN)

171 Rest Of The World Nuclear Medicine Market Outlook, By Applications (2012-2022)

(\$MN)

172 Rest Of The World Nuclear Medicine Market Outlook, By Diagnostics (2012-2022)

(\$MN)

173 Rest Of The World Nuclear Medicine Market Outlook, By Single proton emission
tomography (SPECT) (2012-2022) (\$MN)

174 Rest Of The World Nuclear Medicine Market Outlook, By Cardiology (2012-2022)

(\$MN)

175 Rest Of The World Nuclear Medicine Market Outlook, By Neurology (2012-2022)

(\$MN)

176 Rest Of The World Nuclear Medicine Market Outlook, By Thyroid (2012-2022) (\$MN)

177 Rest Of The World Nuclear Medicine Market Outlook, By Other SPECT applications (2012-2022) (\$MN)

178 Rest Of The World Nuclear Medicine Market Outlook, By Positron emission tomography (PET) (2012-2022) (\$MN)

179 Rest Of The World Nuclear Medicine Market Outlook, By Oncology (2012-2022) (\$MN)

180 Rest Of The World Nuclear Medicine Market Outlook, By Other PET applications (2012-2022) (\$MN)

181 Rest Of The World Nuclear Medicine Market Outlook, By Therapeutics (2012-2022) (\$MN)

182 Rest Of The World Nuclear Medicine Market Outlook, By Thyroid (2012-2022) (\$MN)

183 Rest Of The World Nuclear Medicine Market Outlook, By Bone metastasis (2012-2022) (\$MN)

184 Rest Of The World Nuclear Medicine Market Outlook, By Endocrine tumors (2012-2022) (\$MN)

185 Rest Of The World Nuclear Medicine Market Outlook, By Other therapeutic applications (2012-2022) (\$MN)

I would like to order

Product name: Nuclear Medicine Global Market Outlook - Trends, Forecast, and Opportunity Assessment (2014-2022)

Product link: <https://marketpublishers.com/r/N00B7F296BBEN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N00B7F296BBEN.html>